KRAS G12C is the most common form of KRAS mutation ... hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market. Join the conversation, on Tuesday 28th January @ 10 am ...
FDA approves a new treatment for KRAS G12C-mutated metastatic colorectal cancer, showing significant progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback